Published • loading... • Updated
Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation
- Phrontline Biopharma presented preliminary safety and antitumor findings for TJ101 at the European Society for Medical Oncology Congress 2026 in Madrid.
- The company announced that its Phase Ib trial began after the first patient was dosed.
- Among eight evaluable patients with urothelial carcinoma, six had partial responses, including some who had previously received enfortumab vedotin and pembrolizumab.
- Preliminary activity was reported in squamous non-small cell lung cancer, small cell lung cancer, and prostate cancer, while dose escalation continued.
Insights by Ground AI
29 Articles
29 Articles
Phrontline Biopharma Highlights Encouraging Preliminary Safety and Antitumor Activity of TJ101 Presented at ESMO 2026 and Announces Phase Ib Initiation
Preliminary responses observed in 6 of 8 evaluable urothelial carcinoma patients (75%), including patients previously treated with enfortumab vedotin and pembrolizumab
·Indiana, United States
Read Full ArticleCoverage Details
Total News Sources29
Leaning Left5Leaning Right3Center18Last UpdatedBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
69% Center
L 19%
C 69%
12%
Factuality
To view factuality data please Upgrade to Premium
